回盛生物(300871.SZ)：预计2025年净利润2.35亿元～2.71亿元 同比扭亏

Core Viewpoint - The company expects a significant turnaround in net profit for 2025, projecting a net profit attributable to shareholders of 235 million to 271 million yuan, indicating a year-on-year recovery from losses [1] Group 1: Financial Performance - The company reported a substantial increase in net profit compared to the same period last year, driven by revenue growth from both domestic and international markets [1] - The expected net profit, excluding non-recurring gains and losses, is projected to be between 212.5 million and 248.5 million yuan, also reflecting a year-on-year recovery [1] - The reduction in financial expenses is attributed to the early redemption of convertible bonds, contributing positively to the overall financial performance [1] Group 2: Revenue Drivers - The increase in net profit is primarily due to enhanced revenue, which was supported by technological innovation, improved utilization rates of formulations and active pharmaceutical ingredients, and rising prices of raw materials [1] - The company anticipates that non-recurring gains and losses will impact net profit by approximately 22.5 million yuan during the reporting period [1]